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ABSTRACT: We report the development of a rapid, simple, and robust LC−MS/MS-based enzyme assay using dried blood
spots (DBS) for the diagnosis of pyridox(am)ine 5′-phosphate oxidase (PNPO) deﬁciency (OMIM 610090). PNPO deﬁciency
leads to potentially fatal early infantile epileptic encephalopathy, severe developmental delay, and other features of neurological
dysfunction. However, upon prompt treatment with high doses of vitamin B6, aﬀected patients can have a normal developmental
outcome. Prognosis of these patients is therefore reliant upon a rapid diagnosis. PNPO activity was quantiﬁed by measuring
pyridoxal 5′-phosphate (PLP) concentrations in a DBS before and after a 30 min incubation with pyridoxine 5′-phosphate
(PNP). Samples from 18 PNPO deﬁcient patients (1 day−25 years), 13 children with other seizure disorders receiving B6
supplementation (1 month−16 years), and 37 child hospital controls (5 days−15 years) were analyzed. DBS from the PNPO-
deﬁcient samples showed enzyme activity levels lower than all samples from these two other groups as well as seven adult
controls; no false positives or negatives were identiﬁed. The method was fully validated and is suitable for translation into the
clinical diagnostic arena.
Pyridox(am)ine 5′-phosphate oxidase (PNPO) deﬁciency(OMIM 610090) is an autosomal recessive seizure
disorder caused by impaired activity of the PNPO enzyme,
which catalyzes the oxidation of pyridoxamine 5′-phosphate
(PMP) and pyridoxine 5′-phosphate (PNP) to pyridoxal 5′-
phosphate (PLP), the active form of vitamin B6.
Dietary vitamin B6 is consumed as pyridoxine, pyridoxamine,
and pyridoxal (PN, PM, and PL), their phosphorylated
analogues, and the glucoside of PN.1−4 The hydrolyzed
vitamers are absorbed, and PN and PM undergo phosphor-
ylation prior to their conversion to PLP by PNPO (Figure 1).
The Enzyme Commission (http://www.chem.qmul.ac.uk/
iubmb/enzyme/) catalogues over 140 PLP-dependent enzy-
matic activities. In humans, PLP-dependent enzymes include
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several involved in the synthesis or degradation of amino acids
or amines that serve as neurotransmitters or neuromodulators
in the brain.
Classical PNPO deﬁciency has been described as epileptic
encephalopathy refractive to conventional anticonvulsants and
pyridoxine but responsive to high doses (30−40 mg kg−1
day−1) of PLP.5 In recent years, however, considerable
heterogeneity has been identiﬁed in the phenotype of aﬀected
patients with approximately 40%6 of PNPO-deﬁcient patients
showing some response to pyridoxine. Some of these
individuals have not tolerated a switch in treatment to PLP
with their seizure control worsening. In addition, patients have
presented with seizures after the neonatal period.2,3 Patients
that have severe neonatal epileptic encephalopathy but survive
into infancy have a high disease burden with severe
developmental delay, progressive seizures, and microce-
phaly.2,3,7 However, when diagnosed and treated early, patients
can have a normal neurodevelopmental outcome.8
Diagnosing patients with PNPO deﬁciency can be challeng-
ing. There are many practical diﬃculties in relying upon a
clinical response to PLP or PN as often neonates and infants
can have multisystem pathology and the response to treatment
may not be immediate and total. Additionally, there are other
seizure disorders that respond to treatment with PLP and/or
PN, which cannot be diﬀerentiated from PNPO deﬁciency
using this approach.9 Seizures caused by pyridoxine-dependent
epilepsy (PDE) can be indistinguishable from those caused by a
deﬁciency of PNPO. Hyperprolinaemia type 2 (HPII) or
hypophosphatasia can also cause perinatal B6-responsive
seizures.1 Other neurological disorders known to beneﬁt from
PLP/pyridoxine supplementation include KCNQ2 deﬁciency
and AADC deﬁciency.
Although biochemical ﬁndings that were initially thought to
be characteristic of PNPO deﬁciency can be indicative,5 for
some individuals these may be present only transiently or
absent altogether. A more recent study has suggested that a
high plasma PM concentration can be indicative of patients
with PNPO deﬁciency irrespective of vitamin B6 supplementa-
tion and that this in conjunction with an elevated PM/pyridoxic
acid (PA) ratio is a biomarker for the selective screening of
PNPO deﬁciency.10 However, this study used a small sample
size (n = 6), and it is currently still necessary to conﬁrm these
ﬁndings genetically. Current practice relies on the detection of
mutations in the PNPO gene and subsequent expression studies
to conﬁrm pathogenicity of any variants detected.11,12 This is
often carried out after the exclusion of other B6-responsive
disorders such as pyridoxine-dependent epilepsy due to
mutations in ALDH7A1 (PDE) and can cause a considerable
delay in diagnosis.
Published assays for the determination of PNPO activity
have shown that human erythrocytes convert pyridoxamine 5′-
phosphate (PMP), a substrate of PNPO, to PLP. However,
these assays are laborious, not suitable for routine clinical
diagnosis, require large sample volumes, or use radiolabeled
substrates.13−18 The use of dried blood spots (DBS) from a
heel or ﬁnger-prick is an established method for sample
collection, which was developed initially for the measurement
of phenylalanine levels in the diagnosis of phenylketonuria in
the 1960s.19 Subsequently, the use of DBS to assay enzymes
present in the circulating blood has been reported for various
metabolic disorders.20 The noninvasive collection and simple
transport/storage are a major advantage of DBS.
We have recently established a mass spectrometry-based
method for quantiﬁcation of the individual forms of vitamin
B6
21 and have further developed this to enable us to assay
PNPO activity in DBS. This highly sensitive method is more
speciﬁc than published methods and allows quantiﬁcation of
PNPO activity without using large sample volumes or
radiolabeled substrates. Here, we report the development and
validation of this assay as well as its utility for the analysis of
control and PNPO-deﬁcient patient samples.
■ EXPERIMENTAL SECTION
Sample Collection and Storage of DBS. This study was
approved by the National Research Ethics Service (NRES)
Committee (London, Bloomsbury [REC ref no. 3/LO/0168]).
The majority of control DBS were obtained from patients
attending Great Ormond Street Hospital for Children, London,
UK. Written informed consent was obtained for all subjects,
and inclusion/exclusion criteria are discussed below. DBS
samples were also received from patients with undiagnosed B6-
responsive seizure disorders, after informed consent, from
centers across Europe. DBS for validation of the measurement
of PNPO activity were collected from healthy adults.
Whatman 903 ﬁlter paper was used for sample collection.
Blood, either venous or capillary, was spotted in the middle of
the preprinted circle of a Protein Saver card (GE Healthcare,
Little Chalfont, Bucks, UK). The spotted blood was allowed to
dry for 16−24 h at room temperature (22 °C) prior to the card
being placed in a sealed foil zip-lock bag with desiccant (to
protect from light and humidity) at room temperature for a
maximum of 7 days. DBS samples were then stored at −20 or
−80 °C until analysis.
Cards were visually inspected upon analysis and rejected if
poor sampling protocol was suspected. Care was taken to avoid
sample collection from recipients of blood transfusions within
the preceding 100 days.
Materials. Trizma base, PLP, LC−MS/MS grade acetic
acid, heptaﬂuorobutyric acid (HFBA), PMP, PL, PM, d3-PM,
PA, d2-PA, and PN were purchased from Sigma-Aldrich
(Gillingham, Dorset, UK). Orthophosphoric acid was pur-
chased from BDH Chemicals (Poole, Dorset, UK). PNP was
purchased from Toronto Research Chemicals (Toronto,
Canada). d2-PN and d3-PLP were purchased from CDN
Isotopes (Thaxted, Essex, UK) and Buchem BV (Appeldoorn,
The Netherlands), respectively. 6.1 N (=6.1 M) trichloroacetic
acid (TCA) was purchased from MP Biomedicals (Solon, U.S.).
Whatman desiccant was purchased from Scientiﬁc Laboratory
Supplies (Nottingham, UK). Flavin mononucleotide (FMN)
was purchased from Applichem (Darmstadt, Germany). All
Figure 1. Vitamin B6 metabolism. (a) Pyridoxine, (b) pyridoxal, (c)
pyridoxamine, (d) pyridoxine 5′-phosphate, (e) pyridoxal 5′-
phosphate, and (f) pyridoxamine 5′-phosphate. PK = pyridoxal kinase;
PNPO = pyridox(am)ine 5′-phosphate oxidase.
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water used was puriﬁed by a Millipore Milli-Q Direct 8 system
with a 0.22 μm ﬁlter.
Measurement of PNPO Activity. For each patient sample,
two 3 mm punches (T0 and T30) were taken from the spotted
blood card. These punches were rehydrated in a 1.5 mL
polypropylene tube containing 60 μL of a 40 mmol/L Tris-
phosphate buﬀer, prepared by adjusting a 40 mmol/L Tris
solution to pH 7.6 using 8.5% orthophosphoric acid. The tubes
were then sonicated in a Grant XUBA3 ultrasonic bath for 2
min. Subsequently, 60 μL of a reaction mix containing 800
nmol/L PNP substrate and 3 μmol/L FMN was added to each
tube to a ﬁnal concentration of 400 nmol/L and 1.5 μmol/L,
respectively. 120 μL of a reaction stop mix (0.3 M TCA
containing 50 nmol/L of the internal standard d3-PLP to a ﬁnal
concentration of 0.15 M and 25 nmol/L, respectively) was
added immediately to tube T0 prior to incubation on ice for 45
min. Tube T30 was incubated for 30 min at 37 °C with shaking
at 300 rpm in an Eppendorf Thermomixer C prior to the
addition of 120 μL of reaction stop mix and incubation on ice
for 45 min. After incubation with TCA, all samples were
sonicated for 5 min prior to centrifugation at 16 000g for 10
min at 4 °C. The resulting supernatant, containing the B6
vitamers, was removed and stored at −20 °C until time of
analysis. All samples were recentrifuged at 16 000g for 10 min at
4 °C after thawing, and the supernatants were transferred to
300 μL amber insert vials (Fisher Scientiﬁc). Because of the
known photolability of PLP,22,23 care was taken at all times to
avoid light exposure, and all standards were stored on ice
during experimentation. For long-term storage, B6 vitamer
stock solutions were kept in aqueous form at −80 °C. TCA
addition and subsequent incubation was necessary for the
precipitation of protein found in the DBS, release of protein-
bound PLP into solution, and cessation of enzymatic activity.
Acidic conditions are also known to stabilize the B6 vitamers in
aqueous solution.24
Liquid Chromatography−Mass Spectrometry. Quanti-
ﬁcation of the B6 vitamers and pyridoxic acid was performed
essentially as described in Footitt et al.21 with minor
modiﬁcations. UPLC−MS/MS was carried out using a Waters
Acquity H-Class UPLC system connected to a Waters Xevo
TQ-S triple quadrupole mass spectrometer using electrospray
ionization and multiple reaction monitoring (MRM). All
compounds were detected in positive ion mode. Eight
microliters of sample was ﬂow-injected by the autosampler
onto a Waters Acquity UPLC HSS T3 column (1.8 μm, 2.1 ×
50 mm) protected by a 1.8 μm Acquity UPLC HSS T3 guard
column. The mobile phase components consisted of (A) 3.7%
acetic acid in water with 0.01% heptaﬂuorobutyric acid (HFBA)
and (B) 100% methanol. The gradient proﬁle used is as
detailed in Table S-1, and the ﬂow rate was 0.4 mL/min. A
representative chromatogram can be found in Figure S-1. The
precursor and product ions used for the detection of PLP, PNP,
PMP, PL, PN, PM, PA, d3-PLP, d2-PN, d3-PM, and d2-PA can
be found in Table S-2. The retention times observed as well as
the cone voltages and collision energies used for the analysis of
these compounds are also detailed in Table S-2. The mass
spectrometry settings were as follows: capillary voltage, 2.50
kV; source temperature, 150 °C; desolvation temperature, 600
°C; cone gas ﬂow rate, 150 L/h; desolvation gas ﬂow rate, 1200
L/h; dwell time, 17 ms. Data collection and analysis was
performed using Waters MassLynx software.
PNPO activity was calculated by subtracting the endogenous
PLP measured at 0 min in the T0 DBS punch from the amount
of PLP present after 30 min of incubation of the DBS with PNP
substrate in the T30 DBS punch. The enzyme activity was
calculated and reported as pmol PLP (3 mm DBS)−1 h−1. To
make comparisons with published data, we made the
assumption that a 3 mm DBS punch contains 3.2 μL of
blood,23 and a conversion factor of 0.3125 was used to convert
this activity to pmol PLP μL blood−1 h−1. Although not used to
quantify PNPO activity, concentrations of PNP were routinely
quantiﬁed. During assay optimization, PMP, PL, PN, PM, and
PA were also quantiﬁed. Despite having similar retention times,
all analytes were well diﬀerentiated, and there was no cross talk
between ion pairs except at high PNP concentrations as
discussed below. Calibration curves from 1.25 to 200 nmol/L
were constructed using the analyte:internal standard peak area
ratios of PLP, PNP, and PMP:d3-PLP and were linear over this
range (r2 > 0.99). A calibration curve, over the same range, was
constructed for PM:d3-PM, PA:d2-PA, and PN:d2-PN; these
were also found to be linear (r2 > 0.99). Pyridoxal was not
quantiﬁed using a calibration curve or internal standard as
measurement was only performed in early stages of method
development. The area under the curve (AUC) upon LC−MS/
MS elution was thus used to quantify pyridoxal levels.
Statistical Analysis. All analyses were carried out using
GraphPad Prism version 6.05 for Windows (GraphPad
Software, La Jolla, CA). Statistical analysis was performed
using one-way ANOVA followed by Tukey’s multiple
comparisons test; ** = P < 0.01; **** = P < 0.0001.
■ RESULTS AND DISCUSSION
PNPO Assay Optimization. The DBS assay was evaluated
and optimized with regards to pH, buﬀer, incubation time, and
cofactor/substrate concentrations.
PNPO enzyme activity in erythrocytes has been reported to
be optimal at pH’s between pH 7.1 and 8.0.13,15 The pH
dependence of the enzyme in the DBS was veriﬁed over this
range, and it was found that there was little diﬀerence in PNPO
activity when a 3 mm DBS from an adult control was incubated
at pH’s at or between pH 7−8 (Table S-3). Analysis of the
chromatogram of samples incubated at pHs > 7.8, however,
revealed peak-splitting of PLP. Therefore, all subsequent
incubation conditions were optimized while keeping the pH
constant at 7.6.
The eﬀects of diﬀerent biological buﬀers on PNPO activity
that were capable of buﬀering at pH 7−8 were investigated. A
Tris-HCl buﬀer system, similar to that which we have used
previously for analysis of PNPO activity in Chinese Hamster
ovary cells overexpressing human PNPO,2 was considered
initially. PNPO is regulated by feedback inhibition of its
product, PLP, and because Tris complexes with PLP it would
therefore be expected to minimize any such inhibition.25
However, it was evident that under the conditions used,
approximately 12% of the PLP formed was subsequently
hydrolyzed to PL (data not shown) presumably by the activity
of multiple endogenous phosphatases that are present in blood,
which hydrolyze the 5′ ester bond of PLP. Inorganic phosphate
is known to be a product inhibitor of phosphatase activity;15,26
therefore, a custom 20 mmol/L Tris-phosphate buﬀer (pH 7.6)
was adopted, and at the concentration of phosphate present
negligible PLP hydrolysis was observed (Figure S-2). There was
additional concern, particularly for the analysis of DBS from
individuals on high-dose supplementation where the levels of
B6 vitamers would be elevated, that any endogenous pyridoxal
kinase activity present in the DBS would act on endogenous PL
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levels to form PLP and that PLP measured in the T30 DBS
would not be solely representative of PNPO activity but of
combined PNPO and pyridoxal kinase activity. Previous studies
have shown, however, that pyridoxal kinase requires the
presence of ATP and a divalent cation (e.g., Mg2+) for
activity,27,28 cofactors that are not added to the PNPO reaction
buﬀer. We have conﬁrmed these ﬁndings in our DBS system. In
the absence of exogenous ATP and Mg2+, PN phosphorylation
to PNP was undetectable (Figure S-3).
PNP was chosen as a substrate for the assay rather than PMP
because oxidation of PNP to PLP, under the conditions
employed, was much more rapid than that observed when PMP
was used as a substrate. The Vmax of PNP conversion to PLP
upon the incubation of a 3 mm adult control DBS was found to
be approximately twice that of PMP to PLP (39.5 vs 19.8 pmol
DBS−1 h−1). Equally, the Km for PNP was 0.32 μmol/L as
compared to 0.53 μmol/L for PMP (Figure S-4). The
conversion of PMP (400 nmol/L) to PLP, when incubated
for 30 min with an adult control DBS, was only 14.1% of that
observed when the same concentration of PNP was used as a
substrate (Figure S-5). In addition, the PMP standard utilized
was found to contain a not insigniﬁcant (1−2%) proportion of
PLP. This background of PLP could interfere with measure-
ment of endogenous PLP in the DBS and lead to feedback
inhibition.
A concentration of 400 nmol/L PNP was used for the assay
for several reasons: (i) This concentration of PNP permitted
analysis of the resulting supernatant by UPLC−MS/MS
without further dilution steps. (ii) Upon the investigation of
higher PNP concentrations for the determination of Michaelis−
Menten kinetics, it was noted that there was a small amount of
cross talk between the MRM channels for PNP and d3-PLP
(<1%). Although at a concentration of 200 nmol/L upon
analysis (as in the T0 repeats of the assay in its current form)
the eﬀect was negligible, at higher PNP concentrations (>1
μmol/L) interference was unacceptable and could aﬀect results
through aberrant PLP quantiﬁcation. (iii) Saturation of the
enzyme with substrate will not facilitate detection of PNPO
deﬁciency in patients with mutations that cause an alteration in
the Km of PNPO where the enzyme has residual activity and the
Vmax and Kcat are relatively unaﬀected. By mildly limiting the
substrate concentration but still achieving easily measurable
conversion in controls, it is likely that the diagnosis of PNPO
deﬁciency in patients with “milder” mutations is enabled.
There were concerns that the concentration of FMN, the
cofactor for PNPO, in DBS samples may be dependent upon
the vitamin B2 status of each subject. Indeed, activity in an adult
control measured in the presence of endogenous FMN was
only 61% of that seen when 1.5 μmol/L FMN was added to the
reaction buﬀer, a concentration that we have used previously
when studying PNPO activity in an overexpression system.2 To
ensure that the concentration of FMN used in the assay was
not limiting the activity of PNPO, punches from DBS collected
from the same control subject were incubated with varying
concentrations of FMN. No signiﬁcant diﬀerence in PNPO
activity was observed when 0.75−3 μmol/L FMN was included
in the reaction buﬀer (Figure S-5). A cofactor concentration of
1.5 μmol/L was used for all subsequent experimentation.
PNPO activity as a function of the amount of enzyme was
established by incubating the substrate with an increasing
weight of dried blood spot. Initial experiments showed that it
was possible to accurately quantify PNPO activity using a 3 mm
DBS punch, the weight of which is approximately 26 mg. PLP
production was measured in the presence of varying amounts of
DBS (0−80 mg) prepared using blood from a healthy adult
volunteer. An approximately linear correlation was observed to
44 mg (Figure S-6). No PLP formation was observed when a 3
mm punch from a blank Whatman 903 card was incubated for
30 min under the ﬁnal assay conditions; hence the enzyme
activity in the DBS samples was not corrected.
The linearity of PLP production from PNP, under the
conditions described above, was monitored in two healthy adult
controls and one child hospital control (age 7 months) over
120 min. Product formation increased linearly for the ﬁrst 60
min in all controls (Figure S-7). It was decided that an
incubation time of 30 min would be used for all analyses as this
provided adequate PLP formation for accurate quantiﬁcation by
LC-MS/MS while keeping the incubation time as short as
possible to increase throughput in a clinical diagnostic arena. It
also ensured linearity of the assay in subjects with particularly
high PNPO activity.
Imprecision and Limits of Detection and Quantiﬁca-
tion. To validate assay precision, PNPO activity was measured
in DBS from one healthy adult control. The intra-assay
precision was 7.9% and was determined by measuring the
PNPO activity in 10 diﬀerent DBS punches from the same
individual on 1 day. Interassay variability was determined by
measuring enzyme activity in 10 diﬀerent DBS punches from
the same individual 5 times over a 4 week period. The observed
interassay variability was 10.3%.
For quantiﬁcation of PLP and PNP, the lower and upper
limits of quantiﬁcation (LLOQ and ULOQ) were set at the
lower and upper bounds of the calibration curve created. This
corresponds to concentrations of 1.25 and 200 nmol/L,
respectively. At LLOQ, the signal/noise (S/N) ratio was
greater than 10. The limit of detection (S/N greater than 3)
was therefore lower than 1.25 nmol/L. It was ensured that,
when back-calculated, the values at LLOQ and ULOQ never
deviated from predetermined criteria speciﬁed by the European
Medicines Agency analytical consideration guidelines (<20%
imprecision for LLOQ and <15% for ULOQ). QC standards of
PLP and PNP were analyzed alongside each LC−MS/MS run
to determine precision of measurement. The %CVs of ﬁve
repeated injections of QC standards of 5, 10, 100, and 175
nmol/L were 2.28%, 0.90%, 2.30%, and 3.45%, respectively.
While the concentration of endogenous PLP levels was
below the limits of quantiﬁcation (<1.25 nmol/L in the
reaction/stop mixture, equivalent to 94 nmol/L whole blood)
in controls not on B6 supplementation, in individuals on
supplementation the concentration of endogenous PLP in the
reaction/stop mixture ranged from 2.5−199 nmol/L. Accuracy
of the extraction method of PLP from DBS was investigated to
ensure that a high endogenous concentration of PLP in the T0
punch would not lead to discrepancies in measured PNPO
activity. The intra and interassay %CVs for the extraction of
endogenous PLP in a DBS card collected from a PNPO-
deﬁcient patient on supra-physiological doses (42 mg/kg/day)
of B6 were 5.92 and 7.76, respectively.
Eﬀect of the Presence of Supra-physiological Con-
centrations of B6 Vitamers on Pyridox(am)ine 5′-
Phosphate Oxidase Activity. While DBS were incubated
in a Tris-based buﬀer system to minimize any feedback
inhibition that PLP may have on PNPO activity, there was
concern that PLP present in DBS from patients on supra-
physiological doses may inhibit PNPO activity. DBS from a
healthy adult not on supplementation were incubated with
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increasing concentrations of PLP added to the reaction buﬀer
(0−400 nmol/L) corresponding to concentrations of 0−200
nmol/L in the reaction/stop mixture after TCA precipitation
(Table S-4). The PLP concentrations present in the reaction/
stop mixture observed in controls and PNPO patients on B6
supplementation were 2.5−199 nmol/L. No product inhibition
was seen in the presence of PLP concentrations ≤50 nmol/L.
Product inhibition was observed at concentrations higher than
this with a decrease in PNPO activity by 15−20% in the
presence of 100−150 nmol/L PLP. The majority of patients
analyzed receiving B6 supplements (13/18 PNPO; 14/16
others) had concentrations of PLP < 100 nmol/L in the T0
DBS reaction/stop mixture (data not shown).
PNPO-deﬁcient patients have been reported to have high
concentrations of PMP, and sometimes PNP, in plasma.21
Concentrations of endogenous PNP and PMP were therefore
measured in the T0 DBS punches so that we could evaluate the
eﬀect of these vitamers on PNPO activity. In control samples
from individuals not receiving/on high dose B6 supplementa-
tion (that were not PNPO deﬁcient), the concentrations of
PNP and PMP in the reaction/stop mixture were below the
LLOQ (1.25 nmol/L). As compared to the concentration of
PNP added to the assay (200 nmol/L), this is negligible. The
concentration of PNP and PMP in the reaction/stop mixture of
PNPO-deﬁcient patients ranged from 0−137 and 0−121 nmol/
L, respectively. The total concentration of substrate present in
the reaction mixture (i.e., endogenous and added) of some
PNPO-deﬁcient patients will be higher therefore than that of
control samples. However, as mentioned above, our data show
that the rate of oxidation of PMP using the assay conditions
employed was far lower than that of PNP. When a 3 mm DBS
from an adult control was incubated with 400 nmol/L PMP in
addition to 400 nmol/L PNP (equivalent to 200 nmol/L upon
analysis of the reaction/stop mixture), a small decrease in PLP
formation was identiﬁed; however, this was not statistically
signiﬁcant (Figure S-5). PMP is not thought to inhibit PNPO
activity;25 therefore, high endogenous PMP levels should not
signiﬁcantly aﬀect results.
Pyridox(am)ine 5′-Phosphate Oxidase Activity in
Dried Blood Spots Following Storage. Stability studies
were performed using DBS from a healthy adult control.
Venous blood was collected and immediately spotted onto
Whatman 903 Protein Saver cards. PNPO stability was
evaluated after storage of the card at various temperatures.
Previous studies have shown that ambient humidity can aﬀect
enzyme stability;29−31 hence, duplicate cards were stored, one
without desiccant and the other in a sealed foil bag with
desiccant after drying for 16−24 h. Enzyme activities observed
after storage were compared to the PNPO activity present in a
DBS after the 16−24 h drying period.
DBS collected for short-term stability studies were stored in
the dark at 22 °C for 3, 5, 7, 14, and 28 days with/without
desiccant (Figure 2). All cards were then stored with desiccant
at −80 °C before being assayed on day 28. When stored at
room temperature without desiccant for 3 days, a residual
activity of 83% was seen. This decreased to 52% over the 28-
day period studied. As expected, the decrease in activity was
mitigated when DBS were stored with desiccant in sealed foil
bags after the initial 16−24 h drying period. Residual activity
under these conditions was 92% and 74% after 3 and 28 days,
respectively.
Long-term stability of the enzyme in DBS was determined
after storage for 1, 4, 8, and 12 weeks at 4, −20, and −80 °C,
again after an initial 16−24 h drying period at 22 °C (Figure 3).
After storage for 12 weeks, a reduction in activity of 27% was
measured in those spots stored at 4 °C. In DBS stored at −20
and −80 °C, activity was 92.7% and 87.0%, respectively, as
compared to baseline levels after 12 weeks. Under these
conditions, minimal diﬀerence was seen in the activity of the
enzyme after storage of the DBS without desiccant.
Analysis of Clinical Samples. PNPO enzyme activity was
measured in DBS from 37 child hospital controls (age range 5
days−15 years) and 7 healthy adult controls. These individuals
did not have seizures. Sixteen samples were also collected from
children with other seizure disorders receiving vitamin B6
supplementation in whom either PNPO deﬁciency had been
excluded by Sanger sequencing or another conclusive genetic
diagnosis had been made; this included 2 individuals with
mutations in ALDH7A1, 1 subject with PROSC deﬁciency,32 7
subjects with other genetic seizure disorders, and 6 individuals
in whom the etiological basis of their seizures is unknown (age
range 1 month−16 years). Eighteen samples were collected
Figure 2. Eﬀect of humidity on the short-term stability of the PNPO
enzyme in dried blood spots. Error bars indicate SEM. DBS were
stored in sealed foil bags with desiccant (▲) or under ambient
conditions (■) at room temperature (22 °C). Data points represent
the mean percentage of activity as compared to that found after 1 day
(n = 2).
Figure 3. Eﬀect of temperature (4 °C [●], −20 °C [■], and −80 °C
[▲]) on the long-term stability of the PNPO enzyme in dried blood
spots (DBS). Data points represent the mean percentage of PNPO
activity relative to measurement at time zero. Error bars indicate SEM.
No signiﬁcant diﬀerence was seen in activities of samples with/without
desiccant; the data from DBS stored both with (n = 2) and without (n
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from subjects (age range 1 day−25 years) with known variants
in the PNPO gene (Table S-5). Three of these samples were
from individuals homozygous for the PNPO variant p.R116Q.
We were interested in looking at the eﬀect of p.R116Q as it is
predicted to aﬀect FMN binding and binding of pyridox(am)-
ine 5′-phosphate oxidase monomers to form the dimeric form
of the enzyme; however, previous in vitro studies have
suggested that this variant has high residual activity and indeed
it is present in the ExAC database with an allele frequency of
0.0558, suggesting it could be a polymorphism.33 We have
concluded previously,2 because of its higher incidence in B6-
responsive epilepsy patients relative to the general population,
that it contributes to the pathogenesis of epilepsy and that it
may be a common mutation, perhaps responsible for the
susceptibility locus for genetic generalized epilepsy on 17q21.32
(close to rs72823592).34 Two of the individuals homozygous
for p.R116Q (subjects 3 and 13) receive B6 for the treatment of
their epilepsy; however, subject 4, the sibling of subject 3, has
never had a seizure and is not on B6 supplementation. DBS
from the parents of the two siblings homozygous for p.R116Q
were also analyzed. All DBS samples were transferred into
sealed foil bags after drying at room temperature for 16−24 h
after collection. They were kept for a maximum period of 1
week at room temperature prior to storing at −20 °C or
temperatures lower than this.
The mean activity of PNPO in DBS samples from hospital
controls was 41.7 pmol DBS−1 h−1 (range: 10.0−95.0 pmol
DBS−1 h−1). The activity of PNPO-deﬁcient patients (range:
0.0−4.6 pmol DBS−1 h−1; mean 1.1 pmol DBS−1 h−1) was
signiﬁcantly lower than the controls (p < 0.0001). This PNPO-
deﬁcient cohort includes the 3 samples from the individuals
homozygous for the p.R116Q variant in PNPO. The range for
patients with other seizure disorders receiving vitamin B6
supplementation, similar to that of the hospital controls, was
signiﬁcantly higher than that of the PNPO-deﬁcient patients
(23.0−85.9 pmol DBS−1 h−1; mean = 56.0 pmol DBS−1 h−1).
Seven healthy adult controls displayed activity from 13.8−44.0
pmol DBS−1 h−1 with a mean of 28.3 pmol DBS−1 h−1. The
p.R116Q heterozygous parents of subjects 3 and 4 had
intermediate PNPO activities of 7.1 and 10.8 pmol DBS−1
h−1 (Figure 4). Patients with mutations in PNPO could be
clearly delineated from all of the control groups with the lowest
control having a PNPO activity more than 2-fold greater than
that of the PNPO patient with highest residual activity.
Diﬀerences between the groups were shown to be statistically
signiﬁcant (P values shown in Figure 4). No false positives
were identiﬁed. The large range of PNPO activity seen in
controls could be representative of population diﬀerences
reported previously.13,14 There was no direct correlation of
PNPO activity with age in the samples from control individuals
not receiving B6 supplementation (age range 5 days−15 years
and adult samples). In the future, it will be important to expand
this age range and measure PNPO activity in DBS of babies
born prematurely as Kang et al.35 have reported that fetal
expression of PNPO is relatively low as compared to that of
adults. The mean PNPO activity in 5 control neonates (<1
month of age) not receiving B6 supplementation measured in
this study was 52.7 pmol DBS−1 h−1 (range 41.3−66.3 pmol
DBS−1 h−1). This is not signiﬁcantly diﬀerent from the PNPO
activity seen in controls (>1 month of age) irrespective of
whether they are receiving B6 supplementation or not. The
youngest neonate (5 days of age) had PNPO activity of 64.3
pmol DBS−1 h−1.
The results obtained using the DBS assay were compared to
those from previous assays of erythrocyte PNPO activity
described in the literature. Anderson et al.14 reported mean
PNPO activity levels of approximately 10 nmol PLP gHb−1 h−1,
and similar activity levels were reported more recently by
Figure 4. DBS PNPO enzyme activity in PNPO-deﬁcient patients and control samples. Box plots indicate range, interquartile range, and median.
Statistical analysis was performed using one-way ANOVA followed by Tukey’s multiple comparisons test; ** = P < 0.01; **** = P < 0.0001.
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Mushtaq et al.36 To compare our results directly, two
assumptions had to be made: (1) a 3 mm punch from a DBS
contains 3.2 μL of whole blood, and (2) the mean hemoglobin
level of our sample cohort was 14 gHb/dL (hemoglobin levels
were not available for our subjects). If these assumptions are
accepted, a conversion factor of 2.2 can be used to convert
pmol PLP DBS−1 h−1 to nmol PLP gHb−1 h−1. This gave mean
PNPO activity levels of 62.2 and 91.8 nmol gHb−1 h−1 in our
adult and child control cohorts, respectively (those not
receiving B6 supplementation). Although these values are
signiﬁcantly higher than those reported previously, there are
major diﬀerences in methodology that can account for this
diﬀerence. First, we have used PNP rather than PMP as a
substrate. As mentioned previously, the oxidation of PMP to
PLP under the conditions used is only 14.1% of that observed
when PNP is used as a substrate, that is, 7-fold less. Equally, we
have shown that upon use of PNP as substrate, a lower Km and
higher Vmax are identiﬁed, when compared to PMP. Second,
methods previously published have not added FMN to their
assay and rely on endogenous FMN present in the samples, and
both our results and previous work13 have shown that addition
of FMN increases PNPO activity in vitro.
Recently, Mathis et al.10 have shown that a raised plasma
PM/PA ratio can be used as a diagnostic marker of PNPO
deﬁciency. PM/PA ratios in dried blood spots of 18 PNPO
deﬁcient subjects and 13 individuals from the cohort of controls
receiving B6 supplementation were measured, although it was
not possible to ascertain recovery of these vitamers due to
interconversion in spiked whole blood by endogenous enzymes.
Ratios were found to range from 0.00−0.95 (mean 0.28) and
from 0.00−0.74 (mean 0.09) in subjects with mutations in
PNPO and controls receiving B6 supplementation, respectively
(Figure S-8). Although the PM/PA ratios in patients with
mutations in PNPO were signiﬁcantly higher (p = 0.0059), it
was not possible to use the PM/PA ratio in dried blood spots to
diﬀerentiate PNPO-deﬁcient individuals from controls receiv-
ing B6 for seizure control with certainty.
There are several factors that may explain the diﬀerent
ﬁndings between the two studies. Our study (n = 18 PNPO
patients) has investigated the ratio in DBS, while that of Mathis
et al.10 (n = 6) studied plasma. Plasma samples were not
available in our study. Comparison of whole blood and plasma
B6 vitamer concentrations will be important in the future. The
PNPO genotype may also be inﬂuential, as PNPO-deﬁcient
patients investigated previously were homozygous for either the
c.674G > A (n = 4), c.263 + 2T > C (n = 1), and c.416A > C (n
= 1). In this study, we have studied the ratios of subjects with
14 diﬀerent genotypes (Table S-5), only one of which was
studied previously (c.263 + 2T > C; subject 18). The individual
with this genotype was found to have a raised PM/PA ratio in
both studies. Equally, in those patients for whom supplementa-
tion type was known, a larger proportion of our subjects were
receiving PLP monotherapy for the treatment of their seizures
as opposed to PN: 19/23 overall, 14/17 PNPO deﬁcient versus
2/37 overall, and 2/6 PNPO deﬁcient in Mathis et al.10 Type of
B6 supplementation and dosage could be important if using
PM/PA ratios for diagnosis of PNPO deﬁciency.
The three subjects (3, 4, and 13) homozygous for the
p.R116Q variant had extremely low PNPO activities (<0.2
pmol DBS−1 h−1), while the two parents who were
heterozygous for the p.R116Q PNPO variant had intermediate
PNPO activities of 7.1 and 10.8 pmol DBS−1 h−1. This
contrasts to our previous ﬁndings where variants had been
investigated in a human in vitro HeLa cell lysate expression
system, in which p.R116Q was shown to result in 83% activity
as compared to wild-type PNPO activity.2 We have previously
suggested that p.R116Q contributes to the pathogenesis of
epilepsy. The results of the DBS assay conﬁrm this. The
diﬀerence observed between the two systems with regard to
this variant may be due to how PNPO utilizes PNP as a
substrate, as we have used in this DBS assay, rather than PMP,
as used in the in vitro overexpressed system. Indeed, a patient
homozygous for p.R116Q has previously been reported to have
a normal plasma PM/PA ratio.10 In this study, 2/3 subjects
homozygous for p.R116Q also had low DBS PM/PA ratios.
Why subject 4, the sibling homozygous for this variant, exhibits
negligible activity and has not presented with seizures has yet to
be explained. It may be that there are other environmental or
genetic factors that are implicated. The mother of this subject
received multivitamin tablets containing PN during pregnancy,
and it is possible that this increased the PLP and PL in her
plasma/breast milk to concentrations high enough to provide
adequate intracranial PLP concentrations in the subject as a
fetus/neonate. Accordingly, it is also possible that a “second
hit” is required at another locus for an epileptic phenotype to
become apparent. Further work will be needed to clarify this
and to investigate the eﬀects of p.R116Q on PNPO activity.
There have been reports of liver dysfunction in individuals
receiving high doses (>30 mg kg−1 d−1) of PLP for the
treatment of seizures. In particular, this has been noted in
PNPO-deﬁcient patients.37,38 Transiently raised liver function
tests have also been reported in 14/28 patients with infantile
spasms when receiving 30−50 mg kg−1 d−1 PLP.39 A clear
mechanism behind this pathology has yet to be elucidated, but
it would be prudent to minimize patient exposure to high PLP
doses where possible.40 This DBS assay can identify individuals
receiving PLP supplementation in whom PNPO activity is
normal and could therefore help to assess which patients would
be more likely to tolerate a switch to PN supplementation while
maintaining seizure control. This would help to eliminate
potential liver damage in these individuals. An alternative
treatment approach could be pyridoxal supplementation;
however, this has not been tested clinically.
This DBS assay will also be useful for the diagnosis of
patients in whom only one heterozygous pathogenic variant has
been identiﬁed in the PNPO gene upon molecular genetic
investigation. Subject 6 is heterozygous for the PNPO variant c.
[641dupA]; however, no other pathogenic variant has been
identiﬁed. They had undetectable PNPO activity using our
DBS assay, conﬁrming subject 6 is PNPO deﬁcient.
Currently, in patients with neonatal/infantile seizures, if CSF
analysis shows alterations in neurotransmitter amine metabo-
lites (e.g., raised 3-O-methyldopa; low homovanillic acid, 5-
hydroxyindoleacetic acid) or amino acids (e.g., raised glycine,
threonine) indicative of PLP deﬁciency or low CSF PLP,
urinary α-aminoadipic semialdehyde (α-AASA) is measured to
exclude ALDH7A1 deﬁciency. This DBS assay could, in
combination with the clinical presentation of these individuals,
be used for the simultaneous assessment of PNPO activity
alongside urinary α-AASA measurement. This will aid the
development of protocols for the rapid diagnosis and treatment
of neonatal seizures.
■ CONCLUSIONS
We have developed a novel LC−MS/MS-based assay for the
determination of PNPO activity, which would be suitable for
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translation into the clinical diagnostic setting. The method is
simple, robust, and clearly separates PNPO-deﬁcient patients
from individuals with normal PNPO activity. It does not
require prior enzyme extraction from the DBS nor derivatiza-
tion, requires minimal sample preparation, and can be
performed in 1.5 h, followed by a 6.5 min LC−MS/MS
analytical run. All previously published assays for measuring
PNPO activity have not been suitable for the clinical setting
and often require large sample volumes not possible to obtain
from severely ill neonates. This new rapid DBS PNPO assay
will now allow clinicians to distinguish PNPO deﬁciency from
other disorders, potentially in combination with the plasma or
DBS PM/PA ratio. This will be a powerful tool for clinicians to
help diagnose these patients.
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